4.2 Article

Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1

Journal

PHARMACOGENETICS AND GENOMICS
Volume 16, Issue 7, Pages 515-525

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.fpc.0000215066.29342.26

Keywords

alternative splicing; arylamine N-acetyltransferase; carcinogens; neoplastic transformation; promoter regions; tissue-specific transcription; tumor cells

Funding

  1. NCI NIH HHS [R01 CA034627-21, CA 34627, R01 CA034627] Funding Source: Medline
  2. NIEHS NIH HHS [F30 ES012557, ES 12557, F30 ES012557-03] Funding Source: Medline

Ask authors/readers for more resources

Variable expression of human arylamine N-acetyltransferase 1 (NAT1) due to genetic polymorphism, gene regulation or environmental influences is associated with individual susceptibility to various cancers. Recent studies of NAT1 transcription showed that most mRNAs originate at a promoter, P1, located 11.8kb upstream of the single open reading frame (ORF) exon. We have now characterized an alternative NAT1 promoter lying 51.5 kb upstream of the NAT1 ORF In the present study, analysis of human RNAs representing 27 tissue types by reverse transcriptasepolymerase chain reaction (RT-PCR) and quantitative RT-PCR showed the upstream 51.5 kb promoter, designated P3, to be most active in specific tissues, including kidney, liver, lung, and trachea. All NAT1 P3 mRNAs included W-untranslated region (5'-UTR) internal exons of 61 and 175 nucleotides in addition to the 79 nucleotide 5-UTR exon present in P1 mRNA. CAP-dependent amplification of 5'-P3 mRNA termini defined an 84 bp transcription start region in which most start sites are centrally clustered. The hepatoma-derived HepG2 cell line expressed a high level of P3 mRNA with the same spliced structure and start site pattern as found in normal tissues. A 435-bp minimal promoter was defined by transfection of HepG2 with luciferase expression constructs containing genomic fragments from the P3 start region. These findings imply a fundamental role for P3 in NAT1 regulation and define additional regions for genetic polymorphisms associated with enhanced cancer risk. Pharmacogenetics and Genomics 16:515-525 (c) 2006 Lippincott Williams & Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available